Palmitoyl Tripeptide-1
Collagen-stimulating matrikine peptide and key component of Matrixyl 3000 for comprehensive anti-aging skin renewal.
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Suggested dose
0.002 % – 10 ppm
Compound profile
Scientific & efficacy data
Cosmetic
Peptide profile
Limited human trials
Palmitoyl Tripeptide-1
Under 10 ppm (<0.001%) in finished product · Once daily
Molecular formula
C30H54N6O5
- Mol. weight
- 578.8 Da
- CAS number
- 147732-56-7
- PubChem
- 10231864
- Developed · 2002
- Lipotec S.A. research team
Lipotec S.A. (Lubrizol Corporation)
Amino acid sequence
Pal-Gly-His-Lys (palmitoylated GHK tripeptide)Collagen Production
Directly activates TGF-β pathway in dermal fibroblasts to stimulate synthesis of collagen types I, III, IV, and VII along with other ECM proteins.
Anti-Aging
Clinical studies demonstrate up to 55% collagen density increase and 19% elasticity improvement over 12 weeks of consistent application.
Skin Firmness
Comprehensive ECM remodeling including elastin, glycosaminoglycans, and decorin production restores structural integrity to aging skin.
Dosing
How much do I take?
0.002 % – 10 ppm · once or twice daily
0.002 % – 10 ppm
Once or twice daily
Covers all 2 documented dose levels · timing · dose-adjustment guidance.
Suitability
Is this right for me?
Best for individuals seeking comprehensive collagen stimulation through topical skincare & those with aging skin showing loss of firmness, elasticity, and density
Best for
Individuals seeking comprehensive collagen stimulation through topical skincare
Palmitoyl Tripeptide-1 is particularly well-suited for individuals focused on individuals seeking comprehensive collagen stimulation through topical skincare. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Those with aging skin showing loss of firmness, elasticity, and density
Palmitoyl Tripeptide-1 is particularly well-suited for individuals focused on those with aging skin showing loss of firmness, elasticity, and density. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
People looking for non-invasive alternatives to injectable collagen treatments
Palmitoyl Tripeptide-1 is particularly well-suited for individuals focused on people looking for non-invasive alternatives to injectable collagen treatments. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Those seeking GHK-based skin benefits without copper peptide formulation complexity
Palmitoyl Tripeptide-1 is particularly well-suited for individuals focused on those seeking ghk-based skin benefits without copper peptide formulation complexity. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Consider alternatives if
Do not use if
Use with caution if
Not sure?
Compare Palmitoyl Tripeptide-1 with similar peptides to find the best fit for your goals.
Administration
How do I use it?
Topical
Route
Palmitoyl Tripeptide-1 is administered Topical—no injection required
Best sites
Covers reconstitution · step-by-step technique · storage · a sample daily schedule.
Safety
Is it safe?
4 common side effects · 2 serious
Palmitoyl tripeptide-1 demonstrates excellent cosmetic safety with GRAS/safe-for-use designation in topical formulations at concentrations up to 2%.
No serious adverse events in 20+ years of cosmetic industry use; mild erythema (<1% of subjects) at high concentrations (>5%). Dermal penetration limited to stratum corneum; no systemic absorption in vitro. Compatible with common skincare ingredients.
Cosmetic safety testing database and published dermatology literature confirm collagen synthesis enhancement through procollagen α1(I) gene expression increases (quantitative real-time PCR).
Skin firmness improvements of 20-30% measured through elastometry and mechanical testing over 8-12 weeks application. Dermatological safety per Cosmetic Ingredient Review confirms safety with no irritation at concentrations up to 2%.
Common side effects · experienced by some users
Temporary Skin Irritation
Mild tingling or warmth upon initial application in sensitive individuals. Self-resolving within minutes.
Management: Perform patch test before full-face application. Reduce to once daily if irritation occurs.
Mild Redness
Transient redness at the application site, particularly when combined with other active ingredients.
Management: Simplify skincare routine. Space application of peptides and other actives.
Dryness
Occasional mild dryness when used concurrently with retinoids or strong exfoliants.
Management: Apply hydrating moisturizer over peptide serum. Alternate active ingredients on different days.
Mild Peeling
Minor skin flaking when combined with high-strength chemical exfoliants.
Management: Reduce exfoliant frequency. Ensure adequate moisturization.
Less common
These typically resolve with continued use or dose adjustment.
Stop and seek help if
- Severe or worsening side effects that don't improve with dose adjustment or supportive care
- Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- Your healthcare provider recommends discontinuation based on your clinical response
- Development of any new medical condition that may be contraindicated with Palmitoyl Tripeptide-1
- Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- Abnormal lab results or clinical markers that suggest adverse effects
Palmitoyl Tripeptide-1 should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
With other peptides
- Safe:Palmitoyl Tetrapeptide-7 — May be used together under medical guidance.
- Safe:Hyaluronic Acid — May be used together under medical guidance.
- Safe:Vitamin C — May be used together under medical guidance.
With medications
- Caution:High-Concentration AHAs/BHAs — Use with caution—discuss with your healthcare provider.
- Caution:Benzoyl Peroxide — Use with caution—discuss with your healthcare provider.
- Caution:Very Alkaline Products (pH >8) — Use with caution—discuss with your healthcare provider.
With supplements
- Safe:Multivitamins — Generally safe to take alongside Palmitoyl Tripeptide-1. Space doses apart if taking oral formulations to ensure optimal absorption.
- Safe:Electrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Effectiveness
How do I know it's working?
Limited human trials · first signs weeks 1-4
Evidence level
Limited human trials
Regulatory status
Research compound
Onset of effects
Moderate
(1-2 weeks)
How it works
Palmitoyl-tripeptide-1 is the shortest lipidated signal peptide that stimulates collagen and elastin production in your skin.
The fatty acid attachment helps it penetrate deep into skin layers, where it activates fibroblasts to rebuild the skin's structural support system. This results in firmer, more elastic, and more youthful-appearing skin.
The deeper mechanism
Palmitoyl-tripeptide-1 is a three-amino acid peptide conjugated to palmitic acid that serves as a signal peptide for fibroblast-mediated collagen synthesis.
The palmitic acid moiety increases skin barrier penetration through lipid partitioning into the stratum corneum, allowing the tripeptide to reach viable epidermis and dermis.
The tripeptide sequence activates fibroblast receptors (potentially growth factor receptors or G-protein coupled receptors) that increase type I collagen gene expression through MAPK/ERK and PI3K/Akt pathway activation.
Compared to longer palmitoyl-peptides, the tripeptide has reduced specificity but may avoid potential off-target effects. Palmit-oyl-tripeptide-1 improves skin thickness, elasticity, and hydration through enhanced ECM production.
What to expect
Weeks 1-4
What you might notice
- Cellular-level activation begins
- Fibroblasts respond to TGF-β signaling with increased ECM protein gene expression
- Early improvements in skin texture and hydration may be noticed
What's normal
- Full integration of Palmitoyl Tripeptide-1 into physiological systems is established
- Long-term Palmitoyl Tripeptide-1 response remains personalized to your physiology
- Palmitoyl Tripeptide-1 tolerance is well-maintained with consistent dosing
What's next
- Maintain your established Palmitoyl Tripeptide-1 protocol for sustained benefits
- Continue periodic monitoring to confirm Palmitoyl Tripeptide-1 efficacy
- Review comprehensive Palmitoyl Tripeptide-1 response with your provider
Weeks 4-12
What you might notice
- Collagen and elastin synthesis accelerates
- Measurable improvements in skin firmness, elasticity, and fine line depth
- Clinical studies show significant collagen density increases during this period
What's normal
- Palmitoyl Tripeptide-1 is now achieving steady-state pharmacokinetics
- Measurable changes aligned with Palmitoyl Tripeptide-1's mechanism may appear
- Initial adjustment effects typically resolve by this point
What's next
- Maintain Palmitoyl Tripeptide-1 dosing exactly as established
- Track progress toward intended outcomes in detail
- Review lab work or biomarker changes with your healthcare team
Weeks 12-24+
What you might notice
- Near-maximal collagen density improvement (up to 55% increase)
- Sustained improvements in skin elasticity (up to 19%), hydration (up to 28%), and wrinkle reduction
- Continued use maintains benefits
What's normal
- Full therapeutic effects of Palmitoyl Tripeptide-1 are well-characterized at this point
- Maintenance of Palmitoyl Tripeptide-1's therapeutic effects is typical
- Tolerance patterns with Palmitoyl Tripeptide-1 are generally stable over months
What's next
- Comprehensive assessment of Palmitoyl Tripeptide-1 efficacy should be conducted
- Discuss long-term continuation, cycling, or protocol modifications
- Continue regular monitoring of relevant biomarkers or symptoms
Signs it's working
Treatment Response
- Improvement in the primary symptoms or condition being treated
- Positive changes in relevant lab values or clinical markers
- Consistent, stable response to Palmitoyl Tripeptide-1 over time
- Reduction in symptom frequency or severity
General Well-being
- Improved energy levels and daily functioning
- Better quality of life related to the treated condition
- Manageable or absent side effects indicating good tolerance
- Positive feedback from healthcare provider during check-ups
Not seeing results? Common reasons
- Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
- Insufficient time at target dose—most compounds need several weeks to show full benefits
- Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
- Individual variation in response—genetics, metabolism, and other factors affect outcomes
- Underlying conditions or medications interfering with absorption or effectiveness
- Improper storage leading to degraded product—always verify proper storage conditions
Key research
Questions
Frequently asked
What is the difference between Palmitoyl Tripeptide-1 and GHK-Cu?
Both are based on the same GHK tripeptide sequence. GHK-Cu chelates a copper ion for additional antioxidant and wound-healing properties but requires careful formulation due to copper reactivity. Palmitoyl Tripeptide-1 replaces the copper with a palmitic acid chain, improving skin penetration and formulation stability while maintaining collagen-stimulating activity. They share similar ECM-stimulating mechanisms but differ in delivery and secondary effects.
Why is Palmitoyl Tripeptide-1 combined with Palmitoyl Tetrapeptide-7 in Matrixyl 3000?
The two peptides have complementary mechanisms. Palmitoyl Tripeptide-1 stimulates collagen synthesis through TGF-β activation, while Palmitoyl Tetrapeptide-7 reduces inflammation by inhibiting IL-6 secretion. Together they address both the constructive (building new collagen) and protective (reducing inflammatory degradation) aspects of skin aging simultaneously.
How does Palmitoyl Tripeptide-1 compare to Palmitoyl Pentapeptide-4 (Matrixyl)?
Both stimulate collagen production in fibroblasts, but through slightly different signaling cascades. Palmitoyl Pentapeptide-4 (KTTKS) is a type I procollagen fragment, while Palmitoyl Tripeptide-1 (GHK) is a naturally occurring peptide with broader biological effects including stemness restoration. Palmitoyl Tripeptide-1 stimulates more collagen types (I, III, IV, and VII) and has additional effects on integrin signaling.
Is Palmitoyl Tripeptide-1 safe for sensitive skin?
Yes. Palmitoyl Tripeptide-1 has been assessed as safe for cosmetic use by the CIR (Cosmetic Ingredient Review) panel. It is generally well-tolerated across all skin types, including sensitive skin. A patch test is recommended for individuals with a history of topical allergies.
Can Palmitoyl Tripeptide-1 be used with retinol?
Yes, the two ingredients work through complementary mechanisms and can be used together. However, both can cause mild irritation in sensitive individuals. Consider applying them at different times of day (peptides in the morning, retinol in the evening) or on alternating days if sensitivity occurs.
Further reading
History & related research
History · since 1973
Three tiny amino acids that unlock your skin's natural repair system
Biopeptide CL is one of nature's smallest and most powerful anti-aging tools. It is only three amino acids long, but it sends a message that tells skin cells to make collagen and maintain a youthful glow.
Read the full history of Palmitoyl Tripeptide-1Ready for the protocol?
Every dosing tier, administration route, timing note, and dose-adjustment rule for Palmitoyl Tripeptide-1, on one page.